Published in Protein Sci on March 24, 2017
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 6.96
Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell (2013) 4.02
Immunotherapy: past, present and future. Nat Med (2003) 2.62
Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci (2000) 2.58
Stability engineering of antibody single-chain Fv fragments. J Mol Biol (2001) 2.58
Kinetic partitioning of protein folding and aggregation. Nat Struct Biol (2002) 2.37
FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils. Protein Sci (2004) 2.31
Competing pathways determine fibril morphology in the self-assembly of beta2-microglobulin into amyloid. J Mol Biol (2005) 2.10
Formation of disulfide bonds in proteins and peptides. Biotechnol Adv (2005) 1.20
Tyrosine, phenylalanine, and disulfide contributions to the circular dichroism of proteins: circular dichroism spectra of wild-type and mutant bovine pancreatic trypsin inhibitor. Biochemistry (1999) 1.14
Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry (1999) 1.11
An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett (1998) 1.09
Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry (1998) 1.09
Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J Mol Biol (1999) 0.99
Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel (2008) 0.99
Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr Alzheimer Res (2011) 0.93
Contribution of the intramolecular disulfide bridge to the folding stability of REIv, the variable domain of a human immunoglobulin kappa light chain. Fold Des (1996) 0.90
Disulfide bond formation and its impact on the biological activity and stability of recombinant therapeutic proteins produced by Escherichia coli expression system. Biotechnol Adv (2011) 0.90
Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease. MAbs (2013) 0.89
An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway. Biochem J (2011) 0.88
From alpha to omega with Abeta: targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease. Curr Med Chem (2010) 0.84
Single-chain fragment variable passive immunotherapies for neurodegenerative diseases. Int J Mol Sci (2013) 0.84
Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragment. MAbs (2013) 0.79
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Rev Mol Med (2016) 0.78
The protective effects and underlying mechanism of an anti-oligomeric Aβ42 single-chain variable fragment antibody. Neuropharmacology (2015) 0.77
Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect. PLoS One (2017) 0.75
Towards the improvement in stability of an anti-Aβ single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. Amyloid (2017) 0.75